Feider Stephen 4
4 · Beta Bionics, Inc. · Filed Oct 3, 2025
Insider Transaction Report
Form 4
Feider Stephen
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-10-01$5.10/sh+15,018$76,592→ 59,059 total - Sale
Common Stock
2025-10-01$20.76/sh−14,918$309,698→ 44,141 total - Sale
Common Stock
2025-10-01$21.08/sh−100$2,108→ 44,041 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-10-01−15,018→ 74,677 totalExercise: $5.10Exp: 2033-09-13→ Common Stock (15,018 underlying)
Footnotes (3)
- [F1]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
- [F2]The weighted average sale price for the transaction reported was $20.76 and the range of prices were between $20.03 and $21.03. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.